Horizon’s precision genome-editing platform, genetically-defined cell lines, SyntheTx™ target identification platform, assay development and compound profiling expertise are being combined with traditional early-stage biology and chemistry discovery offerings to create a 21st century drug discovery toolbox that is capable of adding significant value to any target, biomarker, drug discovery or diagnostic research and development program.

Horizon has successfully deployed all of the above tools in this toolbox in its HD-001 program, where a novel synthetic lethal target identified against a previously undruggable gene (K-Ras) has been drugged within an 18 month period. This program is now being partnered with a leading Pharmaceutical partner. This demonstration of the value of deploying its technology platforms, products and services brings great credibility to Horizon’s overall offering.

Learn more about Horizon's Discovery Toolbox through the HD-001 Case Study

Download our Discovery Toolbox presentation

Download a copy of our Company Brochure